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Abstract
Background: Pyrazinamide (PZA) plays an essential part in the shortened six-month tuberculosis (TB) treatment
course due to its activity against slow-growing and non-replicating organisms. We tested whether PZA preferentially
targets slow growing cells of Mycobacterium tuberculosis that could be representative of bacteria that remain after the
initial kill with isoniazid (INH), by observing the response of either slow growing or fast growing bacilli to differing
concentrations of PZA.
Methods: M. tuberculosis H37Rv was grown in continuous culture at either a constant fast growth rate (Mean
Generation Time (MGT) of 23.1 h) or slow growth rate (69.3 h MGT) at a controlled dissolved oxygen tension
of 10 % and a controlled acidity at pH 6.3 ± 0.1. Cultures were exposed to step-wise increases in the concentration of
PZA (25 to 500 μgml−1) every two MGTs, and bacterial survival was measured. PZA-induced global gene expression
was explored for each increase in PZA-concentration, using DNA microarray.
Results: At a constant pH 6.3, actively dividing mycobacteria were susceptible to PZA, with similar responses
to increasing concentrations of PZA at both growth rates. Three distinct phases of drug response could be
distingished for both slow growing (69.3 h MGT) and fast growing (23.1 h MGT) bacilli. A bacteriostatic phase
at a low concentration of PZA was followed by a recovery period in which the culture adapted to the presence of PZA
and bacteria were actively dividing in steady-state. In contrast, there was a rapid loss of viability at bactericidal
concentrations. There was a notable delay in the onset of the recovery period in quickly dividing cells compared
with those dividing more slowly. Fast growers and slow growers adapted to PZA-exposure via very similar mechanisms;
through reduced gene expression of tRNA, 50S, and 30S ribosomal proteins.
Conclusions: PZA had an equivalent level of activity against fast growing and slow growing M. tuberculosis.
At both growth rates drug-tolerance to sub-lethal concentrations may have been due to reduced expression
of tRNA, 50S, and 30S ribosomal proteins. The findings from this study show that PZA has utility against more
than one phenotypic sub-population of bacilli and could be re-assessed for its early bactericidal activity, in
combination with other drugs, during TB treatment.
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Background
An important aim for improving TB treatment is to
shorten the period of antibiotic therapy without increasing
relapse rates or encouraging the development of
antibiotic-resistant strains. Pyrazinamide (PZA) is a key
component of front-line chemotherapy against Mycobac-
terium tuberculosis (M. tuberculosis). It is thought to play
an essential role in the shortened 6-month treatment
course [1, 2] due to its ability to act upon the slow-
growing drug-tolerant organisms or antibiotic resistant or-
ganisms that emerge following treatment with the other
front-line drugs, isoniazid (INH) and rifampicin.
In vitro, PZA is still far less potent than in vivo [3]
and its activity against actively growing bacteria in buff-
ered growth media has been found to be extremely low,
but increases against stationary phase bacteria either
under acidic conditions or if the expression of PZA-
activating enzyme, PncA, is artificially increased [4]. Pre-
viously, Zhang et al., [5] exposed 4-day and 3-month old
cultures to PZA for 3 days and found that the 4-day old
cultures were four-fold less susceptible to PZA than the
stationary phase cultures. Hu et al., [6] also demon-
strated that 100-day old static cultures were more sus-
ceptible to PZA than 4-day and 30-day old cultures. Our
aim was to determine the direct impact of growth rate
on the activity of PZA (in a controlled system where the
pH is fixed) and ascertain whether growth rate impacts
the PZA concentration at which the antibiotic is bac-
teriostatic or bactericidal against M. tuberculosis. We ob-
served populations of either slow growing (constant
69.3 h mean generation time) or fast growing bacilli
(constant 23.1 h mean generation time) in their response
to the effects of PZA exposure, using controlled and de-
fined growth in chemostats [7, 8].
In vivo, PZA is thought to have a sterilising effect
against tubercle bacilli in inflammatory lung lesions,
where the pH is acidic (pH 5.5-pH 6.0) [9]. During in vitro
studies of PZA activity, the acidity of the growth medium
is difficult to control in batch culture and acidified
medium is necessary for the susceptibility testing of PZA
against M. tuberculosis. The optimal pH for the activity of
PZA in vitro is pH 5.6 [5]. However, previously it has been
shown that M. tuberculosis would not grow below pH 5.8
in a hollow fibre model [10], indicating that non-dividing
cells are always likely to be the target organism in every
PZA susceptibility assay that uses pH 5.6. Previously, we
observed that fast growing cells in continuous culture
washed out over a period of a few days after the pH was
reduced to a controlled acidity level of pH 6.0, the optical
density dropped from 2.0540nm down to 0.2540nm within
48 h [11]. The lowest acidity level that M. tuberculosis
could be maintained at in steady-state growth and at a
mean generation time of 23.1 h, was pH 6.2 in chemostat
culture. Consequently, a similar pH was used in the
current studies to enable M. tuberculosis to be grown
under controlled environmental conditions in a chemostat
at either constant slow or fast growth rates.
The major advantage of continuous culture is that it
allows the growth-rate, pH, and oxygen tension to be ac-
curately controlled, and single parameters to be varied
independently of each other [7, 8, 12, 13]. Using this ap-
proach it was possible to observe the effect of different
and controlled growth-rates upon PZA activity in vitro,
under defined growth conditions, and at controlled oxy-
gen tension and acidity levels. As shown previously [8],
such precise control over environmental conditions is
ideal for observing transcriptional responses of M. tuber-
culosis to PZA exposure when grown at different rates.
A better understanding of the phenotype of the popula-
tions that PZA targets, the in vivo conditions under
which it is active, and the mode of action of the drug,
will enable us to develop improved assays for testing
combinations of antibiotics that include PZA.
Methods
Strains, media and antibiotic
M. tuberculosis strain H37Rv (NCTC 7416) was used in
all experiments. Stock cultures were routinely propagated
on Middlebrook 7H10 +OADC agar plates at 37 °C for
3 weeks. Chemostat cultures were grown in CAMR Myco-
bacterium medium (CMM Mod2) [14]. PZA was pur-
chased from Sigma (P7136) and working stocks of 10
mgml−1 were prepared in water and frozen at −20 °C.
Mycobacterial culture at different growth rates, and
exposure to PZA
M. tuberculosis (strain H37Rv) was grown in chemostats
under controlled conditions as described previously [8]
in CMM Mod2 [14], (which contained glycerol as the
limiting nutrient), in a culture volume of 500 ml. Two
independent continuous cultures were performed at two
different growth rates to give a total of four cultures.
Mean generation times (MGT) of either 23.1 h (fast
growth) or 69.3 h (slow growth) were achieved by ma-
nipulating the dilution rates of the culture medium to
0.03 h−1 or 0.01 h−1, respectively. Steady-state cultures
were established under defined and controlled condi-
tions at pH 6.3, at a temperature of 37 °C and at a dis-
solved oxygen tension of 10 % [8, 12]. pH control was
not imposed intially and was commenced when the cul-
ture optical density (OD540nm) rose above 2.0. Once pH
control was initiated, 1 M HCl was added automatically
in response to a pH reading higher than the desired set-
point. The pH was monitored constantly by an in situ
probe (Broadley James). Once the culture density
reached the level required, the pH setpoint was gradually
lowered by 0.1 pH units per MGT, until pH 6.3 was
reached. All cultures were controlled at pH 6.3 by the
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addition of 1 M HCL, in a steady-state, as defined by
turbidity and cell viability, for a minimum of 5 MGT
prior to the onset of PZA-addition [11]. PZA was added
through the sample port, the medium line was simultan-
eously drained, and the supply was switched over to
medium containing PZA at the appropriate drug con-
centration. The antibiotic was added to the culture ves-
sels in step-wise increases in the concentration of PZA
(25 to 500 μgml−1) every 2 MGTs.
Viability assays
The viabliity of cultures were assessed by preparing deci-
mal dilution series of culture samples in triplicate using
sterile phosphate buffered saline as the diluent and plat-
ing 100 μL aliquots of each dilution onto Middlebrook
7H10 + OADC plates, in triplicate. The plates were incu-
bated at 37 °C for 4 weeks before colony forming units
(cfuml−1) were enumerated.
RNA extraction
For each time-point, 20 ml of culture were harvested for
RNA extraction. Extractions and DNase digestion were
performed as described previously [8, 12]. Samples were
added to 4 volumes of guanidine thiocyanate (GTC) lysis
solution (5 M GTC; 5 % lauryl sarcosine; 25 mM Tri-
sodium citrate; 0.5 % Tween 80) and incubated at room
temperature for 1 h. The sample mixture was centrifuged
for 15 min at 1935 × g and the supernatant discarded. The
pellets were re-suspended in 1.2 ml of Trizol (Invitrogen
15596018) and mixed thoroughly. The sample was trans-
ferred to a 2 ml tube containing 0.5 ml of 0.1 mm silica
beads (Fisher Scientific MBR-247-105B) and lysed using a
reciprocal shaker (FastPrep FP120) for 45 s at a speed of
6.5. The supernatant was transferred into a tube contain-
ing 240 μl of chloroform and shaken vigorously for 20 s.
This solution was centrifuged at 2415 × g for 10 min. The
aqueous phase was removed and added to 600 μl chloro-
form, shaken vigorously for 20 s and centrifuged for
10 min at 2415 × g; this process was then repeated. Fol-
lowing the second chloroform precipitation, the aqueous
phase was added to 600 μl isopropanol plus 60 μl sodium
acetate (Sigma Aldrich S7899) and frozen at −70 °C over-
night. Total RNA was isolated from the extractions using
the mirVana™ miRNA Isolation kit (Agilent AM1561) and
DNase I-treated using the DNA-free™ kit (Ambion®
AM1906) as per the manufacturer’s instructions. RNA
was quantified using a nanodrop 3000 and the quality
assessed on an Agilent 2100 bioanalyzer (Agilent Tech-
nologies, CA, USA with an Agilent RNA 6000 Nano Kit
(Agilent, 5067-1511).
RNA labelling
RNA was labelled using the Kreatech ULS™ Fluorescent
Labeling Kit for Agilent arrays (Kreatech EA-023) as
described previously [8]. The labelled RNA was fragmen-
ted by adding 2 μl 10× fragmentation buffer, incubating
for 15 min at 70 °C, then adding 2 μl stop solution
(Ambion® AM8740). Labelled RNA (20 μl) was added to
27.5 μl Kreatech blocking reagent (Kreatech EA-023),
55 μl of 2× Hybridisation buffer and 7.5 μl of molecular
grade water. Arrays were hybridised overnight at 65 °C,
then washed in Gene Expression wash buffer 1 (Agilent
5188-5327) for 1 min at room temperature with agita-
tion, then in Gene Expression wash buffer 2 for 1 min at
37 °C with agitation. Slides were scanned immediately
using an Agilent Scanner.
Transcriptomic analyses
Whole genome gene expression analyses were per-
formed. Microarray experiments were performed using a
custom Agilent tiling array with 180,000 60-mer oligos
evenly tiled across the M. tuberculosis H37Rv genome.
Features were extracted from the array images using
Agilent Feature Extraction Software (v10.7) with local
background correction. Probes were first filtered to only
include those covering annotated genes. Intensity values
were normalised and analysed using GeneSpring soft-
ware (version 12.6 GX). Firstly, quantile normalisation
was applied across the combined slow and fast growth
rate datasets, followed by baseline transformation to the
median of all samples and averaging of the expression
level of all probes across each open reading frame. A 2-
way ANOVA (using a p-value cut-off of P ≤0.05 and
growth rate and MGT as conditions) was used to iden-
tify significantly differentially expressed genes. A further
filter was applied to select genes with at least a two-fold
change in gene expression between time-points of inter-
est. Gene lists derived from all pairwise comparisons can
be found in the Additional file 1. Raw data are deposited
at ArrayExpress [15] under the accession number E-
MTAB-4093.
Results & discussion
The effect of growth rate on the sensitivity of M.
tuberculosis to PZA
M. tuberculosis cultured at a fast growth rate showed a
similar response to increasing concentrations of PZA as
slow growing bacilli. Duplicate cultures at either a fast
growth rate (MGT of 23.1 h) or slow growth rate (MGT
of 69.3 h) achieved a steady state in which the total vi-
able cell numbers remained constant at 1 × 108 cfuml−1
and 7 × 107 cfuml−1, respectively, for a minimum of 5
MGT, at a controlled pH of 6.3 (Fig. 1).
The cultures were exposed to sequential increases in the
concentration of PZA in a step-wise manner every 2
MGTs and bacterial survival was measured. The levels of
PZA used were 25, 50, 100, 250 and 500 μgml−1 (Fig. 1).
The washout rate of the chemostat (the theoretical rate at
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which non-dividing cells are removed from the culture by
dilution) is indicated in Fig. 1 by the red dotted line. A re-
duction in the bacterial numbers that followed this rate
was indicative of a bacteriostatic drug effect. A more rapid
rate in the loss of bacteria indicated a bactericidal effect,
and a less rapid rate indicates a sub-inhibitory effect.
Actively dividing mycobacteria were susceptible to
PZA, and slow and fast growing bacteria were af-
fected similarly (Fig. 1a & b, respectively). Both fast
and slow growing bacilli showed an approximately
log-fold reduction in bacterial numbers following ex-
posure to just 25 μgml−1 PZA, which equated to an
approximately 90 % decrease in cfuml−1 after 2 MGT
(Fig. 1), after which time the growth rate was re-
established. The rate of intial loss of bacterial num-
bers from the system was of a similar magnitude to
the washout rate and was indicative of a bacteriostatic
drug effect and a minimum inhibitory concentration
(MIC) of ≤25 μgmL−1. This MIC agrees with previous
findings by Gumbo et al., in 2009 [10] using the hol-
low fibre. Curiously, they deduced a similar MIC at a
lower level of acidity of pH5.8. They also observed a
lack of killing for four days post PZA-exposure.
Following the increase in PZA concentration to 50
μgml−1, a plateauing in cell titre occurred in the slow
growth rate cultures, at ~ 1 × 107cfuml−1 (Fig. 1a, ap-
proximately 10 % of pre-antibiotic viable cell levels). The
slow growers had adapted to the presence of PZA and
remained in steady-state for 4 MGT through a further
increase in PZA to 100 μgml−1. The fast growth-rate
cultures continued to lose viability during exposure to
50 μgml−1 but then followed a similar but delayed re-
sponse by plateauing in their cell number between 100
and 250 μgml−1 PZA (Fig. 1b). When the PZA concen-
tration reached 250 μgml−1 the bacterial numbers fell in
the fast growing cultures (Fig. 1b) to approximately 1 %
of original pre-PZA levels after 2 MGTs, which contin-
ued following the increase to 500 μgml−1. It is not pos-
sible for us to say whether a PZA concentration of 250
μgml−1 was also bactericidal for the slow growth cultures
(Panel a, Fig. 1) as after one MGT at that concentration
the bacilli in these cultures were still dividing. Death of
the slow growers was observed between 7MGT and 10
MGT. However, this may have been from exposure to a
PZA concentration of 500 μgmL−1 and not 250 μgmL−1.
A time-point at 8 MGT was included for the fast
growers but not the slow growers. This time-point pro-
vides critical information for us to be able to conclude
that bacilli at each growth rate were sterilised by the
same concentration of PZA. It appears that the fast
growers could have been killed at a lower PZA concen-
tration than the slow growers but further time-courses
would need to be performed to be certain of this. By the
end of the PZA-exposure time-course (10 MGT), less
ba
Fig. 1 The viability of M. tuberculosis H37Rv at either a fast growth rate or a slow growth rate in response to PZA exposure. Viability of
Mycobacterium tuberculosis H37Rv growing at either a slow growth rate (69.3 h mean generation time (MGT); Panel a or a fast growth
rate (23.1 h MGT; Panel b The cultures were exposed to sequential increases in the concentration of PZA in a step-wise manner every 2
MGTs and bacterial survival was measured. The levels of PZA used were 25, 50, 100, 250 and 500 μgml−1; these concentrations are indicated on each
graph between the vertical dotted lines to show each exposure period. Each growth rate was cultured in duplicate (solid and dashed black lines). The
washout rate of the culture system is represented by the gradient of the dashed red lines. A reduction in bacterial number (cfuml−1) that followed this
rate was indicative of a bacteriostatic drug effect. A more rapid rate of loss of viable cells indicated a bactericidal effect, and a less rapid rate indicates a
sub-inhibitory effect. The limit of detection (LOD; defined as the level calculated from the presence of a single colony in one technical
replicate) is indicated by the line labelled LOD. The time-points for which transcriptional analyses were performed are indicated as follows:
i) pre-PZA phase, ii) bacteriostatic phase (4 h after the addition of 25 μgml−1) iii) early recovery phase (4 h after the addition of 100
μgml−1 PZA) and iv) late recovery phase (2 MGT after the addition of 100 μgml−1 PZA)
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than 0.1 % of the original viable cell population was
remaining in all cultures. The results show that high
concentrations of PZA will sterilise the population ir-
respective of growth rate. The bactericidal response
observed in our cultures was at a concentration that
was much higher than observed previously in studies
when the environmental pH was lower. The experi-
ments described here were designed to specifically de-
termine the effect of growth rate on PZA efficacy and
therefore a higher pH had to be used to enable cells
to continue to divide.
The mode of action of PZA was described previously
by Zhang et al., in 2003 [16]. PZA, a pro-drug, is con-
verted to pyrazinoic acid (POA) by an amidase (encoded
by gene; Rv2043c, pncA) found in the bacterial cyto-
plasm [17]. POA is excreted from the bacteria and then
it diffuses passively back in through the cell wall as the
protonated molecule (HPOA) when the pH of the bac-
terial environment is acidic. Multiple mechanisms of ac-
tion have been identified for POA; it has been shown to
decrease the proton motive force and ATP synthesis
rates in mycobacterial membranes as well as lowering
cellular ATP levels in Mycobacterium bovis BCG [18].
Further support is given to this by the observations that
some weak acids and energy inhibitors work synergistic-
ally with PZA [19] and mutations in energy production
and ion homeostasis pathways enhance PZA activity
[20]. The reported bactericidal concentration of PZA in
vitro under more acidic condtions at a pH of 5.6 is
50 μg/ml [5]. Bactericidal effects were observed between
250 and 500 μgml−1 PZA in this study for both growth
rates; this reduction in effectiveness (5-fold) is in propor-
tion with the expected fold-decrease in internal POA
concentration commenserate with a less acidic external
condition in our chemostat cultures (pH 6.3) as calcu-
lated using the Henderson-Hasselbalch equation [5, 21].
Previously, it had been shown that the slowing of bacter-
ial growth reduced the activity of an efflux pump, which
is then inefficient at extruding HPOA from the cell,
thereby leading to an accumulation of HPOA and subse-
quently increased bactericidal effects. In our study, we
did not observe any effect of bacterial growth rate on
the overall sterilising activity of PZA. This suggests that
it is not growth rate per se that determines PZA activity;
increased drug activity observed during stationary phase
must be due to other aspects of bacterial metabolism.
PZA has no detectable early bactericidal activity (EBA)
in the first 2 days of treatment [22]; monotherapy ranges
from 0.04 to 0.1 log10cfuml
−1day−1 [9]. However, despite
this lack of efficacy, PZA exerts an effect by shortening
treatment only during the first 2 months of treatment
and not beyond this. Extending the duration of treat-
ment with PZA has no additional benefit in either
humans or murine models [3, 23, 24]. Can we be sure
that PZA is not exerting a profound bacteriostatic effect
against actively dividing organisms during the first phase
of treatment? It has always been assumed that INH
clears the fast growing population during EBA leaving
slow growing drug-tolerant (as opposed to genetically
resistant) bacteria that need to be cleared by other drugs
such as PZA. However, in a recent study we showed that
both fast and slow growing cells persist through INH ex-
posure via different growth rate-specific genotypic and
phenotypic mechanisms [8]. Therefore, we cannot gener-
alise that fast growing bacteria are sterilised during EBA
and slow growing cells are sterilised later during treat-
ment. The contribution of PZA to the clearance of fast
growing bacteria during the first phase of treatment has
not been fully explored but it may be having hidden and
profound effects such as controlling bacterial numbers
or preventing antibiotic resistance from arising. Could
the activity of PZA be improved during the first phase of
treatment by using it in combination with other antibi-
otics that boost its activity? The maximum peak level of
PZA attainable in patients’ blood is 30–60 μgml−1 which
is the optimal killing concentration in vitro at pH 5.6
[25]. More defined and reproducible in vitro systems
that can test combinations of drugs, including PZA,
against M. tuberculosis and achieve lower concentrations
of PZA which deliver more potent bactericidal activity
would help to shorten treatment times. Previously,
Grosset et al., [26] demonstrated in mice that INH
could be having antagonistic effects on the efficacy of
PZA, and that there might be benefits of removing
INH after the first 2 days of treatment. As PZA is a
lead drug in terms of good sterilising activity, it is
important to understand how other drugs have an
impact on PZA efficacy and how we can rationalise
the use of current drugs to optimise its activity. The
postponement of PZA use after the initial bactericidal
phase has been suggested [26] but this may not be
beneficial given the information presented here dem-
onstrating that PZA has a comparable level of activity
against fast and slow growing cells of M. tuberculosis.
It may be more appropriate to optimise combinations
that improve the efficacy of PZA from the start of
treatment. Is there a case for replacing INH with al-
ternative antibiotics that increase the activity of PZA
and do not give rise to resistance in the way that
INH does? This has been demonstrated recently by a
clinical trial of PZA in combination with moxifloxacin
and Pretomanid (PA-824) [27], which showed superior
bactericidal activity in drug-susceptible TB during
8 weeks of treatment. Results were consistent between
drug-susceptible and multi-drug resistant (MDR) TB.
This new regimen is ready to enter phase 3 trials in
patients with drug-susceptible TB and MDR-TB, with
the goal of shortening and simplifying treatment.
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Transcriptional analysis
Three distinct phases of response to PZA can be distin-
guished in cells growing at slow or fast growth rates
(Fig. 1, panels a & b, respectively) There was an initial
loss of bacteria as PZA was added to the system at in-
hibitory levels (25 μgml−1; “bacteriostatic phase”),
followed by a phase in which bacilli had adapted to the
presence of PZA and were actively dividing in steady
state (“recovery phase”). Finally a rapid loss of culture
viability was observed once the levels of PZA became
bactericidal (“bactericidal phase”). The most notable dif-
ference in the response to PZA between cells growing at
the two growths rates was that the slow growing bacteria
plateaued earlier in the recovery phase than the fast
growers (Fig. 1). Global gene expression was analysed to
see if the mechanisms of adaptation to pyrazinamde in
the ‘recovery phase’ were different between bacilli cul-
tured at different growth rates. RNA was extracted at
time-points prior to PZA-addition (“pre-PZA phase”
Fig. 1.i)), during the bacteriostatic phase (4 h after the
addition of 25 μgml−1, “bacteriostatic phase” Fig. 1.ii)),
and during the recovery period (4 h after the addition of
100 μgml−1 PZA, “early recovery phase” Fig. 1.iii), and 2
MGT after the addition of 100 μgml−1 PZA, “late recov-
ery phase” Figure.iv)). The RNA was analysed by whole
genome DNA microarray and the data are deposited in
ArrayExpress, accession no. E-MTAB-4093 [15]. The
two time-points within the recovery phase were selected
to cover the overlap in the recovery periods for the two
growth rates. The 4 h timepoint was early on in the re-
covery of the fast growers and mid-recovery for slow
(“early recovery” Fig. 1.iii)), whereas the time-point at
2MGT after this was at the end of the recovery period
for both growth rates (“late recovery” Fig. 1.iv)). No
genes were differentially expressed between the pre-PZA
phase (Fig. 1.i)) and the bacteriostatic phase (Fig. 1.ii))
under slow growth using selection criteria of an Anova
p-value of less than 0.05 and a minimum fold change of
two. In contrast, four genes were up-regulated under fast
growth between these phases: Rv2645 (uncharacterised),
Rv2738c (uncharacterised), Rv3221 (biotynylated protein
TB7.3), and Rv3018c (uncharacterised PPE family pro-
tein), (Additional file 1: Table S1). Following this, com-
parisons were made between the pre-PZA phase and the
recovery phases. There were 341 differentially expressed
genes in the early recovery phase (Fig. 1.iii)) compared
to pre-PZA phase (Fig. 1.i)) in slow growing cells, which
consisted of 115 up-regulated genes and 226 down-
regulated genes (Fig. 2. & Additional file 1: Table S2). In
the late-recovery phase (Fig. 1.iv)) there were 415 genes
differentially expressed under slow growth, which con-
sisted of 148 up-regulated genes and 267 down-
regulated genes (Fig. 2. & Additional file 1: Table S2).
There were 85 shared up-regulated genes and 204
shared down-regulated genes across the two timepoints
in the recovery phase (Fig. 1 iii) and iv)) for slow growth
(Fig. 2. & Additional file 1: Table S2.). In the fast-
growing cultures there were only two differentially
expressed genes in the early recovery phase (Fig. 1.iii)),
both of which were up-regulated. In the late recovery
phase (Fig. 1iv)), 38 genes were differentially expressed,
which consisted of 10 up-regulated genes and 28 down-
regulated genes (Fig. 2. & Additional file 1: Table S3).
Differentially expressed genes were enriched for
functions encoding Ribosomal proteins and tRNAs
To determine whether differentialy expressed genes were
significantly enriched for particular functions, functional
annotation clustering reports were generated using the
DAVID 6.7 bioinformatic resource [28] with Uniprot IDs
Fig. 2 Significantly differentially expressed genes during PZA-exposure. Numbers of genes up-regulated (in green) or down-regulated (in red), with
a fold-change greater than two-fold and ANOVA p-value less than 0.05, in the early recovery phases (4 h after the addition of 100 μgml−1 PZA)
and late recovery phases (2 mean generation times (MGT) after the addition of 100 μgml−1 PZA) compared to the pre-PZA phases under
fast growth rates (23.1 h MGT) and slow growth rates (69.3 h MGT). The numbers shown in brackets refer to the subset of genes in each
case that encode either tRNAs or ribosomal protein components
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as the input. A Bonferroni-corrected EASE-value cut-
off of 0.01 (EASE-value being an alternative name for
the one-tail Fisher Exact Probability Value used to
measure gene-enrichment in annotation terms, com-
pared to proportions of these genes encoded within
the genome) was employed along with a minimum
gene number per category of five genes (i.e. a cat-
egory cannot be considered to be enriched unless at
least five genes from a function are present). The
functional annotation clustering report groups similar
categories of annotations together into clusters. None
of the up-regulated genes were significantly enriched
for any functional categories. Under slow growth, the
226 down-regulated genes in the early recovery phase
and the 267 down-regulated genes in the late recov-
ery phase (Fig. 2.) were significantly enriched in 15
categories as defined by the GO ontology database
[29], the Protein Information Resource (PIR) [30], and
the KEGG pathway database [31] (Table 1.). All 15
categories were clustered into a single group by DA-
VID, and no other categories outside the group were
enriched. All categories relate to ribosomal functions.
From the fast growth rate cultures, there were no sig-
nificantly enriched categories in the early recovery
phase, but the 31 down-regulated genes in the late
recovery phase (Fig. 2.) showed significant enrichment
for the same 15 ribosomal function related categories
seen under slow growth conditions.
At a gene-specific level, during the early recovery
phase, eight tRNA-encoding genes and 26-ribosomal-
protein encoding genes were down-regulated in the
slow growing cultures (Table 1, Fig. 2. brackets,
Table 2.), with a single up-regulated gene encoding a
ribosomal protein (Rv2442, 50s ribosomal protein L21).
In contrast, no genes of this function were differentially
expressed in the fast growing cultures. By late recovery
under slow growth, there were 17 tRNA-encoding
genes and 31 ribosomal-protein encoding genes show-
ing significant down-regulation compared to the pre-
PZA phase. There were also 6 tRNA-encoding genes
and seven ribosomal protein encodoing genes down-
regulated in the fast growing bacteria in the late recov-
ery phase (Table 3.). The delayed down-regulation seen
during fast growth was co-incident with the delayed
plateau in culture viability.
It is challenging to ascertain which of the PZA targets
make the biggest contribution to cell death. With so
many modes of action does PZA act predominantly
upon the the same target and in all bacterial phenotypes
under different growth conditions? Given the multiple
modes of action, we were interested in which phenotypic
mechanisms were employed by fast and slow growing
bacilli to enable them to overcome the effects of the
antibiotic and to observe any obvious growth-rate spe-
cific mechanisms. It was postulated previously that POA
disrupts bacterial membrane energetics and inteferres
Table 1 DAVID Functional annotation clustering of genes that were down-regulated in M. tuberculosis exposed to PZA under different
growth rates in early and late recovery
Slow growth (69.3 h MGT) Fast growth (23.1 h MGT)
Down-regulated
in early recovery
Down-regulated
in late recovery
Down-regulated
in early recovery
Down-regulated
in late recovery
Annotation scheme Annotation Count Bonferroni
corrected
EASE-value
Count Bonferroni
corrected
EASE-value
Count Bonferroni
corrected
EASE-value
Count Bonferroni
corrected
EASE-value
KEGG_PATHWAY ribosome 25 4.00E-24 28 1.70E-26 n/a n/a 7 4.20E-08
GOTERM_MF_FAT structural constituent of ribosome 25 1.60E-21 28 4.10E-25 n/a n/a 7 1.10E-08
SP_PIR_KEYWORDS ribonucleoprotein 25 3.60E-21 28 3.40E-24 n/a n/a 7 1.90E-06
GOTERM_MF_FAT rRNA-binding 21 1.00E-20 23 2.30E-23 n/a n/a 4 1.10E-03
SP_PIR_KEYWORDS rRNA-binding 21 7.80E-21 23 4.30E-23 n/a n/a 4 8.10E-03
SP_PIR_KEYWORDS ribosomal protein 25 3.50E-20 28 5.00E-23 n/a n/a 7 3.10E-06
GOTERM_MF_FAT structural molecule activity 25 5.50E-20 28 2.60E-23 n/a n/a 7 2.50E-08
GOTERM_CC_FAT ribosome 25 2.50E-19 28 1.30E-21 n/a n/a 7 9.80E-05
GOTERM_CC_FAT ribonucleoprotein complex 25 8.80E-19 28 5.60E-21 n/a n/a 7 1.30E-04
GOTERM_BP_FAT translation 29 1.10E-17 32 1.00E-19 n/a n/a 7 9.20E-06
SP_PIR_KEYWORDS RNA-binding 22 7.50E-16 25 1.50E-18 n/a n/a 4 4.50E-02
GOTERM_MF_FAT RNA binding 26 1.80E-14 27 1.80E-14 n/a n/a 5 1.50E-03
GOTERM_CC_FAT ribosomal subunit 10 8.60E-09 10 3.60E-08 n/a n/a 4 3.20E-03
A corrected EASE-value of 0.01 and minimum gene number per category of five was used to perform functional annotation clustering on all down-regulated
genes in the early recovery phase (4 h after the addition of 100 μgml−1 PZA) or the late recovery phase (2 MGT after the addition of 100 μgml−1 PZA) compared
to the pre-PZA phase
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Table 2 Ribosomal and tRNA associated genes down-regulated in M. tuberculosis exposed to PZA under slow growth
Gene expression fold change from
pre-PZA to early recovery phase
(100 μgml−1 for 4 h)
Gene expression fold change from
pre-PZA to iv) late recovery phase
(100 μgml−1 for 2 MGT)
Gene name UniProt ID Annotation
−4.81 −11.22 tRNA-Val tRNA-Val
−3.23 −10.01 tRNA-Glu tRNA-Glu
−3.99 −9.34 tRNA-Lys tRNA-Lys
−5.13 −8.95 Rv0700 P0A5X0 30S ribosomal protein S10
−2.63 −8.62 tRNA-Gly tRNA-Gly
−3.52 −8.60 tRNA-Thr tRNA-Thr
−4.86 −8.15 tRNA-Arg tRNA-Arg
−5.22 −7.36 Rv0704 P95052 50S ribosomal protein L2
−4.49 −7.33 tRNA-Met tRNA-Met
−4.68 −6.35 Rv0703 P95051 50S ribosomal protein L23
−4.29 −6.16 Rv1298 P66187 50S ribosomal protein L31
−1.65 −6.13 tRNA-Leu tRNA-Leu
−2.33 −5.97 tRNA-Ser tRNA-Ser
−4.08 −5.88 Rv0710 P95058 30S ribosomal protein S17
−1.65 −5.43 tRNA-Pro tRNA-Pro
−3.70 −5.20 Rv0705 P0A5X4 30S ribosomal protein S19
−1.44 −4.83 tRNA-Tyr tRNA-Tyr
−3.56 −4.82 Rv0709 P95057 50S ribosomal protein L29
−4.32 −4.82 Rv0702 P60729 50S ribosomal protein L4
−3.99 −4.72 Rv0722 P66181 50S ribosomal protein L30
−3.09 −4.66 Rv0701 P60442 50S ribosomal protein L3
−3.76 −4.17 Rv0716 P62403 50S ribosomal protein L5
−3.32 −3.98 Rv0717 P0A5X2 30S ribosomal protein S14 type Z
−3.48 −3.79 Rv0682 P41196 30S ribosomal protein S12
−3.01 −3.69 Rv0715 P60627 50S ribosomal protein L24
1.03 −3.68 tRNA-Cys tRNA-Cys
−3.45 −3.61 Rv1643 P66105 50S ribosomal protein L20
−2.99 −3.56 Rv0723 P95071 50S ribosomal protein L15
−1.44 −3.38 tRNA-Trp tRNA-Trp
−2.97 −3.32 Rv2412 P66505 30S ribosomal protein S20
−3.07 −3.22 Rv0683 P41194 30S ribosomal protein S7
−4.07 −3.05 Rv0718 P66625 30S ribosomal protein S8
−3.13 −3.04 Rv1642 P66271 50S ribosomal protein L35
−2.59 −3.02 Rv0714 P66069 50S ribosomal protein L14
−2.79 −2.92 Rv0707 P0A5X6 30S ribosomal protein S3
−1.06 −2.91 5S_rRNA ribosomal RNA
−2.44 −2.91 Rv0721 P66574 30S ribosomal protein S5
1.03 −2.84 tRNA-Asp tRNA-Asp
−1.14 −2.67 tRNA-His tRNA-His
−1.10 −2.65 tRNA-Phe tRNA-Phe
−1.45 −2.64 tRNA-Ile tRNA-Ile
1.00 −2.45 23S rRNA ribosomal RNA
−1.41 −2.39 Rv0640 P66056 50S ribosomal protein L11
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with energy production [16]. Stationary phase bacilli
might have a lower membrane potential than actively
dividing log-phase bacteria, which could explain the
increased activity of PZA against stationary phase
bacteria observed previously. No gene expression
changes were observed for genes encoding functions
related to membrane potential. Bacilli in fast and slow
growth cultures may not have exhibited much differ-
ence in membrane potential explaining the similar re-
sponse to PZA-exposure. Understanding the specific
differences between bacterial stationary phase and
slow growth might enable us to dissect out the range
of activities that PZA has against bacilli in different
phenotypic states. Fast growers and slow growers
were adapting to PZA-exposure via very similar
mechanisms. The only functions that were differen-
tially expressed under each growth rate, that were
also enriched for function using DAVID analyses,
were genes encoding tRNA, 50S and 30S ribosomal
proteins, which were down-regulated during the re-
covery phase. This may go some way to explaining
why the populations at both growth rates were adapt-
ing and establishing new steady-states, but at a lower
cell density. The maximum cell number sustainable
on the available nutrient was simply less because of a
reduction in level of protein that was being translated
leading to a subsequent decrease in available target.
Recently, Shi et al., [32] found that POA binds the
ribosomal protein S1 (RspA), which is a vital protein
for trans-translation, and inhibits the trans-translation
activity required for efficient protein synthesis. Muta-
tions in rpsA (gene Rv1630) result in PZA-resistance,
and are alternative mechanisms of resistance to muta-
tions in pncA [33–35]. Trans-translation is essential
for rescuing stalled ribosomes during translation in
non-replicating organisms and inhibition of this process
could be one mechanisms by which PZA targets persisting
organisms. Bacteria require trans-translation to respond
Table 2 Ribosomal and tRNA associated genes down-regulated in M. tuberculosis exposed to PZA under slow growth (Continued)
1.00 −2.27 16S rRNA Ribosomal RNA
−2.01 −2.27 Rv0720 P66076 50S ribosomal protein L18
−1.84 −2.17 Rv0719 P66311 50S ribosomal protein L6
−2.15 −2.07 Rv0055 P69230 30S ribosomal protein S18 1
−1.67 −2.03 Rv1630 O06147 30S ribosomal protein S1
−2.35 −1.92 Rv1644 P94978 possible 23S rRNA methyltransferase tsnR
Genes encoding tRNAs or ribosome component proteins that were down-regulated by at least two fold (with an ANOVA p –value of less than 0.05) in M. tubercu-
losis under slow growth in the early recovery phase (4 h after the addition of 100 μgml−1 PZA) and/or the late recovery phase (2 MGT after the addition of 100
μgml−1 PZA) compared to the pre-PZA phase
Table 3 Ribosomal and tRNA associated genes down-regulated in M. tuberculosis exposed to PZA under fast growth
Fold change from pre-PZA to
early recovery phase
(100 μgml−1 for 4 h)
Fold change from pre-PZA
to late recovery phase
(100 μgml−1 for 2 MGT)
Gene name UniProt ID Annotation
1.12 −2.03 tRNA-Glu tRNA-Glu
−1.45 −2.07 Rv0704 P95052 50S ribosomal protein L2
−1.43 −2.10 Rv0723 P95071 50S ribosomal protein L15
−1.02 −2.11 tRNA-Thr tRNA-Thr
−1.07 −2.20 tRNA-Lys tRNA-Lys
−1.12 −2.26 tRNA-Arg tRNA-Arg
−1.55 −2.31 Rv0703 P95051 50S ribosomal protein L23
−1.60 −2.33 Rv0700 P0A5X0 30S ribosomal protein S10
−1.51 −2.40 Rv0722 P66181 50S ribosomal protein L30
−1.14 −2.42 tRNA-Val tRNA-Val
−1.79 −2.45 Rv0709 P95057 50S ribosomal protein L29
−1.90 −2.72 Rv0710 P95058 30S ribosomal protein S17
−1.10 −2.04 tRNA-Met tRNA-Met
Genes encoding tRNAs or ribosome component proteins that were down-regulated by at least two fold (with an ANOVA p –value of less than 0.05) in M. tubercu-
losis under fast growth in the early recovery phase (4 h after the addition of 100 μgml−1 PZA) and/or the late recovery phase (2 MGT after the addition of 100
μgml−1 PZA) compared to the pre-PZA phase
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to stress, pathogenesis, and differentiation, which indicates
that fast growing organisms also require trans-translation
to overcome stress [36]. Based on this mode of action for
PZA, it follows that fast-growing organisms would be tar-
geted by PZA. Increased PZA efficacy against fast growing
cells could be enabled by potentiators that create stress/
reduce metabolism, such as energy inhibitors, in fast
growers [37, 38].
The recovery period co-incident with the down-
regulation of ribosomal protein encoding genes seen
in this study might reflect a mechanism to reduce
the production of toxic proteins caused by the inhib-
ition of trans-translation [39]. Alternatively adapta-
tion may have occurred through an increase in the
mutant frequency and diversity of mutations as pre-
viously shown in the adaptation of fast and slow
growing M. tuberculosis to INH exposure and we
would expect (as shown for INH-exposure) that there
would be a difference in the mutant profile between
the two different growth rates. Much is understood
about how M. tuberculosis adapts to PZA-exposure
by the development of resistance mutations in pncA and
more recently mutations have been shown in panD [20],
which encodes aspartate-alpha-decarboxylase involved in
the synthesis of β-alanine that is a precursor for panto-
thenate and co-enzyme-A biosynthesis [40] and may be
yet another target for PZA.
Conclusions
PZA has an equivalent level of activity against fast
growing and slow growing M. tuberculosis under the
conditions tested here. Both populations appeared to
adapt to PZA-exposure via reduced expression of
tRNA, 50S, and 30S ribosomal proteins. Understand-
ing the subtle differences between bacterial growth
rate and growth phase will enable us to dissect out
the range of activities that PZA has against bacilli in
different phenotypic states and aid the development
of drug combinations containing PZA. The contribu-
tion of PZA to the clearance of actively dividing ba-
cilli during the first phase of treatment has not been
fully explored. However, the findings from this study
show that PZA has utility against fast growing bac-
teria and it demonstrates that the assessment of drug
combinations containing PZA, used early in treat-
ment, warrants further investigation.
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